Provided by Tiger Fintech (Singapore) Pte. Ltd.

Theriva Biologics

1.50
+0.08686.14%
Volume:25.73K
Turnover:37.84K
Market Cap:4.17M
PE:-0.08
High:1.50
Open:1.44
Low:1.41
Close:1.41
Loading ...

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire
·
10 Apr

Theriva™ Biologics Announces Positive Outcomes From the Second Meeting of the Independent Data Monitoring Committee for Virage, the Company’s Phase 2B Clinical Trial of Vcn-01 in Combination With Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (Pdac)

THOMSON REUTERS
·
31 Mar

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

GlobeNewswire
·
19 Mar

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire
·
19 Mar

Theriva Biologics Reports 2024 Financial Results and Progress

TIPRANKS
·
08 Mar

Theriva Biologics FY 2024 GAAP EPS $(19.03) Beats $(24.11) Estimate

Benzinga
·
07 Mar

Theriva Biologics files to sell 7.69M shares of common stock, warrants

TIPRANKS
·
11 Dec 2024

Theriva Biologics Inc Files for Offering up to 7.7 Mln Shares and Warrants

THOMSON REUTERS
·
11 Dec 2024

Theriva Biologics Advances VCN-01 with FDA Guidance

TIPRANKS
·
05 Dec 2024

Theriva Biologics announces U.S. FDA guidance of Phase 3 study design

TIPRANKS
·
05 Dec 2024

Theriva Biologics Inc: FDA Advised That on-Going Virage Phase 2B Study Should Not Be Expanded Into a Phase 3 Study

THOMSON REUTERS
·
05 Dec 2024

Theriva Biologics Inc - to Request Additional FDA Meeting After Virage Study Completion

THOMSON REUTERS
·
05 Dec 2024

Theriva Biologics Inc - FDA Recommends Stand-Alone Phase 3 Study for Vcn-01

THOMSON REUTERS
·
05 Dec 2024

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

GlobeNewswire
·
05 Dec 2024

Theriva Biologics Highlights Key Achievements in Q3 2024

TIPRANKS
·
14 Nov 2024

Theriva Biologics Is Maintained at Buy by Maxim Group

Dow Jones
·
14 Nov 2024

Theriva Biologics Inc : Maxim Group Cuts Target Price to $6 From $25

THOMSON REUTERS
·
13 Nov 2024

Theriva Biologics: Q3 Earnings Snapshot

Associated Press Finance
·
12 Nov 2024

Theriva Biologics reports Q3 EPS ($6.81) vs. ($4.85) last year

TIPRANKS
·
12 Nov 2024

Theriva Biologics Q3 EPS $(6.81) Misses $(6.25) Estimate

Benzinga
·
12 Nov 2024